Effects on rat urinary kallikrein excretion of bumetanide, bendroflumethiazide and hydralazine.
Single and/or repeated administrations of bumetanide, bendroflumethiazide and hydralazine to normotensive and spontaneously hypertensive rats resulted in an increase of urinary kallikrein excretion. No correlation was found with sodium output. The role of the increased plasma renin activity is discussed and it is suggested that the activation of the renal kallikrein-kinin system is related to the increase in renal blood flow.
D000284:Administration, Oral; D000818:Animals; D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000494:pharmacology*; D002034:Bumetanide / Q000008:administration & dosage / Q000494:pharmacology*; D004232:Diuretics / Q000494:pharmacology*; D006830:Hydralazine / Q000008:administration & dosage / Q000494:pharmacology*; D006973:Hypertension / Q000201:enzymology; D007610:Kallikreins / Q000652:urine*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012083:Renin / Q000097:blood; D012964:Sodium / Q000652:urine; D013997:Time Factors
D004232:Diuretics; D002034:Bumetanide; D006830:Hydralazine; D001539:Bendroflumethiazide; D012964:Sodium; D007610:Kallikreins; D012083:Renin